Jana Spaldova

Jana Spaldova

Auto-generated profile, based on publicly available information

Jana Spaldova

Department of Biochemistry and Microbiology, Faculty of Chemical and Food Technology , Slovak University of Technology in Bratislava , Radlinskeho 9, SK-81237 , Bratislava , Slovak Republic

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2023 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
BPBranislav Pavilek
Branislav Pavilek
DBDušan Bortňák
Dušan Bortňák
JŠJakub Šofranko
Jakub Šofranko
LŠLucia Šofranková
Lucia Šofranková
JŠJana Špaldová
Jana Špaldová
VMViktor Milata
Viktor Milata

1 January 2026 in Open Life Sciences
Verified
Journal Article
Open access
NDNatalia Dostalkova
Natalia Dostalkova
LŠLucia Šofranková
Lucia Šofranková
JSJana Spaldova
Jana Spaldova
BPBranislav Pavilek
Branislav Pavilek
EPEster Pisarova
Ester Pisarova
BLBoris Lakatoš
Boris Lakatoš
Acute myeloid leukemia is a severe hematologic malignancy that predominantly affects older adults and is characterized by high biological variability. One of the main challenges in its treatment is the development of multidrug resistance, often mediated by the overexpression of P-glycoprotein (ABCB1). This transport protein actively expels cytotoxic drugs from cells, reducing the effectiveness of chemotherapy and worsening patient prognosis. Although several generations of P-glycoprotein inhibitors have been developed, their clinical use is significantly limited due to their negative side effects. In recent years, attention has shifted toward natural substances and well-known drugs with broad applications. A promising candidate is amantadine, a lipophilic compound with a stable structure, originally used to treat influenza and Parkinson’s disease. This study focuses on investigating the potential of its derivatives in combating multidrug resistance in acute myeloid leukemia. The results demonstrate that the newly synthesized adamantane derivatives, particularly E-A2, exhibit significant cytotoxic activity in acute myeloid leukemia cell lines, including P-glycoprotein-expressing resistant variants. Importantly, E-A2 was able to induce both apoptotic and necrotic cell death and maintained its activity in multidrug resistant models.